MiMedx GroupMDXG
About: MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Employees: 837
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
17% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 24
14% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 64
1.36% more ownership
Funds ownership: 69.0% [Q1] → 70.36% (+1.36%) [Q2]
0% more funds holding
Funds holding: 217 [Q1] → 218 (+1) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
18% less capital invested
Capital invested by funds: $773M [Q1] → $635M (-$138M) [Q2]
33% less call options, than puts
Call options by funds: $353K | Put options by funds: $525K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Cantor Fitzgerald Ross Osborn | 68%upside $12 | Overweight Maintained | 31 Jul 2025 |
Financial journalist opinion
Based on 4 articles about MDXG published over the past 30 days
